Head-to-head evidence
ensifentrine vs HRS-9821
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: PDE3/PDE4 · full Chronic Obstructive Pulmonary Disease pipeline
ensifentrine · Ohtuvayre
Marketed by Merck & Co. and partners
NCT04542057 · Phase 3 · completed
This was a large (790-patient), randomized, quadruple-blinded, placebo-controlled Phase 3 trial with a hard clinical/lung-function primary endpoint (change in FEV1 area under the curve over 12 hours), and the ensifentrine group showed a statistically significant improvement over placebo on that primary comparison. The randomization, blinding, active placebo control, adequate sample size, and clear statistically significant result in the favorable direction together support a strong grade.
Next expected readout: March 2027 · NCT05270525 (registry estimate)
HRS-9821
Developed by Jiangsu Hengrui Pharmaceuticals
NCT05622864 · Phase 1 · completed
The study is described as randomized and blinded, but the available record does not clearly show a placebo or comparator arm alongside the two active-dose groups, so how controlled the comparison actually is cannot be fully confirmed. Its primary measure is also safety monitoring rather than the lung-function endpoints, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ensifentrine's landscape · HRS-9821's landscape